Savara (SVRA) Change in Taxes (2017 - 2018)
Savara (SVRA) reported Change in Taxes of $156000.0 for Q3 2018, up 31.09% year-over-year from $119000.0 in Q3 2017, and down 57.14% on a QoQ basis from $364000.0 in Q2 2018.
Savara (SVRA) has 2 years of Change in Taxes data on file, last reported at $156000.0 in Q3 2018.
- Quarterly Change in Taxes rose 31.09% year-over-year to $156000.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $1.1 million (changed N/A YoY) and the FY2017 annual result came in at $454000.0, up 215.52% from the prior year.
- Change in Taxes eased to $156000.0 in Q3 2018 per SVRA's latest filing, from $364000.0 in the prior quarter.
- Across five years, Change in Taxes topped out at $873000.0 in Q1 2018 and bottomed at -$331000.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 156,000.00 |
| Sep 30, 2018 | 156,000.00 |
| Jun 30, 2018 | 364,000.00 |
| Jun 30, 2018 | 364,000.00 |
| Mar 31, 2018 | 873,000.00 |
| Mar 31, 2018 | 873,000.00 |
| Dec 31, 2017 | -331,000.00 |
| Dec 31, 2017 | -331,000.00 |
| Sep 30, 2017 | 119,000.00 |
| Sep 30, 2017 | 119,000.00 |
| Jun 30, 2017 | 501,000.00 |
| Jun 30, 2017 | 501,000.00 |
| Mar 31, 2017 | 165,000.00 |
| Mar 31, 2017 | 165,000.00 |